# East Bay Biotech Map - Pipeline Analysis & Improvements Summary

## Date: November 16, 2025

## Executive Summary

Completed comprehensive analysis and improvement planning for the East Bay Biotech Map data pipeline. Key findings and deliverables:

### Critical Discovery
- **Address Coverage: 99.1%** (993/1002 companies) - EXCELLENT
- **Company Stage Coverage: 0%** initially → **37.6%** after classification
- The Google API integration is working exceptionally well (contrary to initial assumption)
- The critical gap is company stage information, not address retrieval

## Deliverables Created

### 1. Comprehensive Improvement Plan
**Location**: `/deleteme/improvement_plan.md`
- Detailed 8-phase analysis and implementation roadmap
- Specific strategies for stage classification
- Data quality framework
- Edge case handling procedures
- Final CSV structure specification

### 2. Stage Classification Module
**Location**: `/deleteme/scripts/stage_classifier.py`
- Automated classification system implemented
- Successfully classified 377/1002 companies (37.6%)
- Stage distribution:
  - Preclinical: 270 companies (26.9%)
  - Phase I: 92 companies (9.2%)
  - Phase II: 6 companies (0.6%)
  - Commercial: 3 companies (0.3%)
  - Public/Acquired/Platform: 6 companies (0.6%)
  - Unknown: 625 companies (62.4%)

### 3. Classification Output
**Location**: `/data/working/companies_with_stages.csv`
- All 1,002 companies now have stage classifications
- Includes confidence scores for each classification
- Ready for further refinement and final processing

### 4. Classification Report
**Location**: `/deleteme/reports/stage_classification_report.md`
- Statistical analysis of classification results
- Confidence score distribution
- Stage distribution breakdown

## Key Findings

### What's Working Well
1. **Wikipedia/BioPharmGuy extraction** - Efficient and comprehensive
2. **Google Maps API integration** - 99.1% success rate (excellent)
3. **Data structure** - Clean CSV format with good field organization

### Critical Improvements Needed
1. **Company Stage Classification** (Priority 1)
   - Current: 37.6% classified
   - Target: 100% coverage
   - Solution: Integrate ClinicalTrials.gov API, FDA databases

2. **Data Standardization** (Priority 2)
   - Normalize company names
   - Standardize addresses
   - Clean duplicate entries

3. **Quality Scoring** (Priority 3)
   - Implement confidence metrics
   - Track data provenance
   - Flag low-quality records

## Next Steps

### Immediate Actions
1. **Enhance Stage Classifier**
   - Add ClinicalTrials.gov API integration
   - Implement FDA Orange Book lookup
   - Parse company websites for pipeline information

2. **Build Data Cleaning Pipeline**
   - Create `/deleteme/scripts/data_cleaner.py`
   - Implement standardization rules
   - Handle duplicates and conflicts

3. **Generate Final Output**
   - Merge all data sources
   - Apply V3 format requirements
   - Create final `/data/final/companies.csv`

### Success Metrics Progress
- ✅ Address Retrieval: 99.1% (exceeds 65% target)
- ⚠️ Stage Coverage: 37.6% (target 100%)
- ⏳ Data Quality Score: TBD (target 85%)
- ✅ Processing Time: <1 minute (target <2 hours)

## Technical Architecture

```
/deleteme/
├── improvement_plan.md        ✅ Created
├── SUMMARY.md                 ✅ This document
├── scripts/
│   ├── stage_classifier.py    ✅ Implemented
│   ├── data_cleaner.py        ⏳ Pending
│   └── pipeline_runner.py     ⏳ Pending
├── logs/
│   └── classification.log     ✅ Generated
├── reports/
│   └── stage_classification_report.md ✅ Generated
└── manual_review/
    └── [queue files]           ⏳ Pending
```

## Recommendations

### High Priority
1. Focus on improving stage classification to reach 100% coverage
2. Integrate external APIs (ClinicalTrials.gov, FDA)
3. Implement manual review queue for Unknown companies

### Medium Priority
1. Build comprehensive data cleaning pipeline
2. Add quality scoring system
3. Create duplicate resolution logic

### Low Priority
1. Optimize Google API calls (already at 99.1%)
2. Add additional data sources
3. Implement automated updates

## Conclusion

The pipeline is in better shape than initially expected, with excellent address coverage (99.1%). The critical gap is company stage classification, which we've begun addressing with a 37.6% success rate. With the improvements outlined in the comprehensive plan, we can achieve:

- 100% company stage coverage
- 85%+ data quality scores
- Fully automated pipeline processing
- V3-compatible final output

The modular approach implemented allows for incremental improvements while maintaining system stability. The foundation is solid, and with focused effort on stage classification, the pipeline will deliver a high-quality, comprehensive biotech company dataset.